A multicenter, prospective, randomized controlled clinical trial of Yiqijianpi Anticancer Prescription for the prevention and treatment of colorectal adenomatous polyps.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084694

Enrollment

Unknown

Registered

2024-05-23

Start date

2024-05-25

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal adenomatous polyps

Interventions

Chinese Medicine Group:After the first endoscopic removal of colorectal polyps, continuous oral administration of traditional Chinese medicine (mainly to Yiqijianpi and detoxify method, the prescripti

Control group:According to 5% of the drug content of the treatment group, the placebo drug of the control group was made.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Study 1: Clinical observation of TCM syndrome types in patients with colorectal adenomatous polyps: (1) Adults aged 18-80 years old, TCM syndrome type is spleen deficiency syndrome; (2) After polypectomy, the patient has colorectal adenoma confirmed by histological intestinal polyposis examination within 3 days (including adenomatous polyps, tubular adenomas, tubulo-villous adenomas and villous adenomas); (3) Sign the informed consent form and be able to cooperate with the study; Study 2: A multicenter, prospective, randomized controlled clinical trial of Yiqijianpi Anticancer Prescription for the prevention and treatment of colorectal adenomatous polyps: (1) adults aged 18-80 years; (2) Within 1 month of all intestinal polyps removed, and the histological intestinal polyposis test confirmed to be colorectal adenoma (including adenomatous polyps, tubular adenomas, tubulo-villous adenomas and villous adenomas); (3) Sign the informed consent form and be able to cooperate with the study

Exclusion criteria

Exclusion criteria: (1) Patients with serious underlying diseases, (2) patients with early cancer or malignant tumors confirmed by histological intestinal polyposis examination, and (3) patients with mental disorders or other conditions who cannot cooperate; (4) Those who regularly take aspirin, non-steroidal anti-inflammatory drugs, COX2 inhibitors, calcium or vitamin D and other drugs (5) Those who are allergic to drugs; (6) Subjects who are considered by the investigators to be unsuitable to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Study 1: Distribution of tongue images in patients with colorectal adenomatous polyps.;Study 1: Pulse distribution in patients with colorectal adenomatous polyps.;Study 1: TCM syndrome type distribution in patients with colorectal adenomatous polyps.;Study 2: Occurrence of colorectal polyps: Observe the incidence of colorectal polyps at 6, 12, and 24 months, including the number, size, location, and pathological nature of polyps.;Study 2: General Condition: TCM Score.;	—

Measure

Time frame

Study 1: Distribution of tongue images in patients with colorectal adenomatous polyps.;Study 1: Pulse distribution in patients with colorectal adenomatous polyps.;Study 1: TCM syndrome type distribution in patients with colorectal adenomatous polyps.;Study 2: Occurrence of colorectal polyps: Observe the incidence of colorectal polyps at 6, 12, and 24 months, including the number, size, location, and pathological nature of polyps.;Study 2: General Condition: TCM Score.;

—

Countries

China

Contacts

Public ContactWusheng Li

The Affiliated Traditional Chinese Medicine Hospital to Southwest Medical University

58422840@qq.com+86 139 8275 8088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026